Revvity (RVTY)

Executive Summary

Revvity (NYSE: RVTY) is a global diagnostics and life sciences company that emerged from PerkinElmer's 2023 rebranding. The company operates two segments: Discovery & Analytical Solutions, serving research and applied markets with instruments and reagents, and Diagnostics, providing clinical tests and software for reproductive health, immunodiagnostics, and infectious disease. Revvity's integrated platform approach positions it well in the growing precision medicine and diagnostics market. The company has benefited from strong demand in its life sciences tools business and has been streamlining operations to improve margins. Despite macroeconomic headwinds, Revvity maintains a solid balance sheet and generates steady cash flow, enabling investment in innovation and strategic acquisitions. The stock trades at a reasonable valuation relative to peers, with potential upside from new product launches and expansion in high-growth areas like oncology and infectious disease testing.

Upcoming Catalysts (preview)

• Q3 2026Q2 2026 Earnings Release90% success
• Q3 2026Launch of Next-Gen Diagnostics Platform60% success
• Q3 2026Strategic Acquisition in Immunodiagnostics40% success